Savient Pharma (SVNT) Posts Q4 GAAP Loss of 1c; Launches KRYSTEXXA in U.S.
Tweet Send to a FriendGet Alerts SVNT Hot Sheet
Price: $0.57 -1.72%
Revenue Growth %: +34.3%
Financial Fact:
Investment income, net: 33K
Today's EPS Names:
TARO, SENEA, UQM, More
Revenue Growth %: +34.3%
Financial Fact:
Investment income, net: 33K
Today's EPS Names:
TARO, SENEA, UQM, More
Trade SVNT Now!
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) reported Q4 GAAP loss of $0.01, which may not compare to the analyst estimate of ($0.26). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.01 million.
The company also announced the U.S. commercial launch of KRYSTEXXA (pegloticase).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The company also announced the U.S. commercial launch of KRYSTEXXA (pegloticase).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Infoblox (BLOX) Tops Q3 EPS by 5c; Issues Outlook
- Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
Create E-mail Alert Related Categories
Corporate News, Earnings, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
